Quantcast

Presentation at Leading Cardiovascular Magnetic Resonance Meeting Highlights Comprehensive CMR Exam in Clinically Feasible Scan Time

January 17, 2014

HeartVista, developers of advanced, real-time centric magnetic resonance imaging (MRI) applications, announced today the presentation of a clinical abstract highlighting their novel software platform during the SCMR/ISMRM workshop at the 17th Annual Society for Cardiovascular Magnetic Resonance meeting in New Orleans, LA.

(PRWEB) January 17, 2014

This abstract describes HeartVista’s intuitive imaging system that can perform a comprehensive CMR exam in 30 to 45 minutes. Using a real-time environment, interfacing with a GE scanner, real-time color flow, 2D perfusion, and 3D delayed-enhancement images were obtained using the HeartVista cardiac protocol. Comparisons of images obtained during arrhythmia using traditional breath-held SSFP CINE application and the HeartVista free-breathing SSFP application were also presented.

"We are pleased to present clinical experiences with our system at this important conference," stated Juan Santos, PhD, CEO of HeartVista, Inc. "We believe that a comprehensive and time-effective cardiac imaging system could improve the patient experience and facilitate a broader adoption of CMR."

About HeartVista

HeartVista, Inc., is a privately-held Bay-area early-stage medical device company actively developing real-time Magnetic Resonance Imaging (MRI) software. The HeartVista software is an accessory to a whole-body MRI; this software intends to provide a comprehensive cardiac MRI solution, supporting the clinical evaluation and quantification of cardiovascular structure, anatomy, composition, and function in high spatial and temporal resolution. HeartVista technology originated in the Magnetic Resonance Systems Research Laboratory (MRSRL) at Stanford University, and the company is funded by Small Business Innovation Research (SBIR) awards from the National Institute of Health (NIH) as well as from venture capitalist sources.

Availability following FDA 510(k) review.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/01/prweb11493475.htm


Source: prweb



comments powered by Disqus